Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases: Observations from a VALDIG multicenter study.
Perez-Campuzano V, Rautou PE, Marjot T, Praktiknjo M, Alvarado-Tapias E, Turco L, Ibáñez-Samaniego L, González-Alayón C, Puente Á, Llop E, Simón-Talero M, Álvarez-Navascués C, Reiberger T, Verhelst X, Tellez L, Bergmann JB, Orts L, Grassi G, Baiges A, Audrey P, Trebicka J, Villanueva C, Morelli MC, Murray S, Meacham G, Luetgehetmann M, Schulze Zur Wiesch J, García-Pagán JC, Barnes E, Plessier A, Hernández-Gea V; ERN RARE-LIVER; a study of VALDIG, an EASL consortium and REHEVASC.
Perez-Campuzano V, et al. Among authors: morelli mc.
JHEP Rep. 2024 Aug 22;6(12):101191. doi: 10.1016/j.jhepr.2024.101191. eCollection 2024 Dec.
JHEP Rep. 2024.
PMID: 39583091
Free PMC article.